drugset / Trial / NCT02973269
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Phase 2
Terminated
7 enrolled
Revance Therapeutics, Inc.
Wake Forest University Health Sciences · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Timeline
- Start
- 2016-11-14
- Primary completion
- 2017-05-31
- Completion
- 2017-05-31
Outcome
Outcome not reported
Stopped: “New trial with same indication initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 240 iu | Intramuscular |